Pregnancy Complications May Signal a Higher Lifetime Heart Risk
Women who experience problems such as high‑blood‑pressure disorders, gestational diabetes or early birth are being flagged as having a greater chance of heart disease later in life. New research highlights these pregnancy events as early warning signs and calls for better, worldwide tools to predict and manage that risk.
Key takeaways
- Adverse pregnancy outcomes (APOs) like hypertension, diabetes and preterm birth can reveal hidden susceptibility to future cardiovascular disease (CVD) [3].
- Existing CVD risk calculators, built mainly in high‑income settings, may mis‑estimate risk for women from low‑ and middle‑income countries, especially because age‑related effects differ [1].
- Global studies stress the need for integrated, equitable follow‑up after APOs, but clear guidelines and prevention trials are still missing [2,3].
Why pregnancy matters for heart health
Pregnancy stresses the circulatory system like a natural stress test. When a woman develops a hypertensive disorder of pregnancy (HDP) – a condition of high blood pressure that appears only during pregnancy – it may expose an underlying weakness in blood‑vessel regulation [3]. The same logic applies to gestational diabetes, where the body cannot control blood sugar during pregnancy, and to preterm birth, which often follows placental problems. Each of these complications has been linked to a higher chance of heart attacks, strokes or chronic hypertension later on [3].
The Lancet series on cardiovascular disease in pregnancy notes that these links are biologically plausible, but the exact pathways remain under study [2]. What is clear, however, is that women who experience any APO should be seen as having a “sex‑specific” risk factor for later CVD [3].
Gaps in risk prediction across the world
Most current CVD risk equations were derived from data collected in wealthy nations. When researchers applied a high‑income country model to a diabetic cohort in a non‑high‑income country, they found systematic errors, especially in how age influenced risk estimates [1]. Updating the age coefficient and other predictor weights improved the model’s calibration – the ratio of expected to observed events moved close to 1.0 for both men and women [1].
This suggests that simply transplanting a tool from one setting to another can misclassify women’s risk, potentially leaving high‑risk individuals without proper monitoring. The study recommends a feasible approach: adjust key predictor coefficients rather than rely on simple recalibration [1].
What still needs to be done
The Lancet reviews point out that, despite growing awareness, many health systems lack structured follow‑up for women after an APO [2,3]. There are no universally accepted guidelines on how often to screen, which tests to use, or what preventive therapies might work best for this group. Moreover, no large‑scale trials have tested interventions specifically aimed at women with a history of APOs [3].
Researchers call for “implementation research” to discover the best ways to integrate APO history into routine CVD risk assessment and to develop equitable care models that work in both rich and poorer countries [2,3].
Looking ahead
Pregnancy may be the first clue that a woman’s heart is under pressure. Recognizing APOs as early indicators could shift prevention upstream, but only if risk tools are adapted for diverse populations and if health systems create clear pathways for long‑term monitoring. Until those gaps are filled, women who have faced pregnancy complications should discuss their history with a health professional and stay alert to heart‑health warning signs.
